Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

byBenzinga Newsdesk

September 13, 2022

1 minute read

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

Warren Buffett-Backed BYD Outsells Nio, XPeng And Li Auto Combined In September

By Shanthi Rexaline

Today, 7:48 PM

BYD Company Limited (Pink: BYDDF), which has the backing of billionaire investor Warren Buffett, emerged as the leader in Chinese new energy vehicles sales in September.

BYDDF

News

iSpecimen Announces Addition Of Reference Lab In New York To ‘support commercial and government customers focused on COVID-19 research’

By Bill Haddad

Today, 7:48 PM

LEXINGTON, Mass., Jan. 13, 2022 /PRNewswire/ -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online marketplace for human biospecimens, today announced

ISPC

FDA
News

Seagen Says FDA Grants Regular Approval, Expands Indication For PADCEV For Patients With Locally Advanced Or Metastatic Urothelial Cancer

By Benzinga Newsdesk

Today, 7:48 PM

Seagen Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced the U.S. Food and Drug Administration (FDA) granted

SGEN

$1000 Invested In Centene 15 Years Ago Would Be Worth This Much

By Benzinga Insights

Today, 7:48 PM

Centene (NYSE:CNC) has outperformed the market over the past 15 years by 12.83% on an annualized basis producing an average annual return of 19.78%. Currently, Centene has a market capitalization of $48.21 billion.

CNC

Guggenheim Downgrades Rubius Therapeutics to Neutral

Related Posts

Warren Buffett-Backed BYD Outsells Nio, XPeng And Li Auto Combined In September

iSpecimen Announces Addition Of Reference Lab In New York To ‘support commercial and government customers focused on COVID-19 research’

Seagen Says FDA Grants Regular Approval, Expands Indication For PADCEV For Patients With Locally Advanced Or Metastatic Urothelial Cancer

$1000 Invested In Centene 15 Years Ago Would Be Worth This Much